Michael Ulz

Stock Analyst at Baird

(4.15)

# 464

Out of 4,876 analysts

115

Total ratings

50.82%

Success rate

14.97%

Average return

Main Sectors:

Top Industries:

Stocks Rated by Michael Ulz

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	KPTI Karyopharm Therapeutics	Maintains: Outperform	$54 → $42	$4.49	+835.41%	6	May 13, 2025
	SLN Silence Therapeutics	Maintains: Overweight	$45 → $25	$5.54	+351.26%	12	May 9, 2025
	VKTX Viking Therapeutics	Maintains: Overweight	$105 → $102	$28.17	+262.09%	3	Apr 24, 2025
	ALNY Alnylam Pharmaceuticals	Maintains: Equal-Weight	$284 → $268	$318.25	-15.79%	10	Apr 11, 2025
	KYTX Kyverna Therapeutics	Maintains: Overweight	$40 → $20	$3.47	+476.37%	2	Apr 1, 2025
	CABA Cabaletta Bio	Maintains: Overweight	$30 → $22	$1.70	+1,194.12%	6	Apr 1, 2025
	AARD Aardvark Therapeutics	Initiates: Overweight	$29	$13.86	+109.24%	1	Mar 10, 2025
	YMAB Y-mAbs Therapeutics	Maintains: Underweight	$11 → $7	$4.78	+46.44%	7	Mar 5, 2025
	IOVA Iovance Biotherapeutics	Maintains: Outperform	$24 → $20	$1.74	+1,049.43%	4	Feb 28, 2025
	THRD Third Harmonic Bio	Downgrades: Equal-Weight	$20 → $5	$5.45	-8.17%	5	Feb 12, 2025
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$18 → $10	$1.74	+474.71%	2	Feb 3, 2025
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$46 → $96	$56.28	+70.58%	4	Jan 28, 2025
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$48 → $52	$10.05	+417.41%	2	Aug 14, 2024
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Equal-Weight	$110 → $115	$128.15	-10.26%	9	Jul 12, 2024
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$53 → $57	$50.52	+12.83%	3	Jun 18, 2024
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Equal-Weight	$36 → $27	$16.07	+68.01%	4	May 13, 2024
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Equal-Weight	$3 → $7	$1.10	+536.36%	8	Feb 27, 2024
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Equal-Weight	$45 → $48	$39.78	+20.66%	4	Nov 3, 2023
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Outperform	$15 → $27	$10.50	+157.14%	2	Aug 16, 2023
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Equal-Weight	$30 → $20	$2.11	+847.87%	3	Mar 24, 2023
	XXXX XXXXXXXXXXXXXXXX Upgrade	Initiates: Overweight	$45	$2.59	+1,637.45%	1	Feb 1, 2023
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$20 → $10	$0.68	+1,371.67%	3	Jan 27, 2023
	XXXX XXXXXXXXXXXXXXXX Upgrade	Downgrades: Equal-Weight	$3	$2.41	+24.48%	1	Jan 27, 2023
	XXXX XXXXXXXXXXXXXXXX Upgrade	Upgrades: Equal-Weight	$18 → $30	$5.31	+464.97%	1	Jan 27, 2023
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Equal-Weight	$25 → $30	$1.22	+2,359.02%	3	Mar 30, 2022
	XXXX XXXXXXXXXXXXXXXX Upgrade	Initiates: Outperform	$45	$10.02	+349.10%	1	Oct 8, 2020
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Outperform	$12 → $20	$0.33	+6,053.85%	2	May 28, 2020
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Outperform	$85 → $80	$37.13	+115.46%	3	Nov 3, 2017
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Outperform	$12 → $15	$5.69	+163.62%	3	Jul 12, 2017

Karyopharm Therapeutics

May 13, 2025

Maintains: Outperform

Price Target: $54 → $42

Current: $4.49

Upside: +835.41%

Silence Therapeutics

May 9, 2025

Maintains: Overweight

Price Target: $45 → $25

Current: $5.54

Upside: +351.26%

Viking Therapeutics

Apr 24, 2025

Maintains: Overweight

Price Target: $105 → $102

Current: $28.17

Upside: +262.09%

Alnylam Pharmaceuticals

Apr 11, 2025

Maintains: Equal-Weight

Price Target: $284 → $268

Current: $318.25

Upside: -15.79%

Kyverna Therapeutics

Apr 1, 2025

Maintains: Overweight

Price Target: $40 → $20

Current: $3.47

Upside: +476.37%

Cabaletta Bio

Apr 1, 2025

Maintains: Overweight

Price Target: $30 → $22

Current: $1.70

Upside: +1,194.12%

Aardvark Therapeutics

Mar 10, 2025

Initiates: Overweight

Price Target: $29

Current: $13.86

Upside: +109.24%

Y-mAbs Therapeutics

Mar 5, 2025

Maintains: Underweight

Price Target: $11 → $7

Current: $4.78

Upside: +46.44%

Iovance Biotherapeutics

Feb 28, 2025

Maintains: Outperform

Price Target: $24 → $20

Current: $1.74

Upside: +1,049.43%

Third Harmonic Bio

Feb 12, 2025

Downgrades: Equal-Weight

Price Target: $20 → $5

Current: $5.45

Upside: -8.17%

Feb 3, 2025

Maintains: Overweight

Price Target: $18 → $10

Current: $1.74

Upside: +474.71%

Jan 28, 2025

Maintains: Overweight

Price Target: $46 → $96

Current: $56.28

Upside: +70.58%

Aug 14, 2024

Maintains: Overweight

Price Target: $48 → $52

Current: $10.05

Upside: +417.41%

Jul 12, 2024

Maintains: Equal-Weight

Price Target: $110 → $115

Current: $128.15

Upside: -10.26%

Jun 18, 2024

Maintains: Overweight

Price Target: $53 → $57

Current: $50.52

Upside: +12.83%

May 13, 2024

Maintains: Equal-Weight

Price Target: $36 → $27

Current: $16.07

Upside: +68.01%

Feb 27, 2024

Maintains: Equal-Weight

Price Target: $3 → $7

Current: $1.10

Upside: +536.36%

Nov 3, 2023

Maintains: Equal-Weight

Price Target: $45 → $48

Current: $39.78

Upside: +20.66%

Aug 16, 2023

Maintains: Outperform

Price Target: $15 → $27

Current: $10.50

Upside: +157.14%

Mar 24, 2023

Maintains: Equal-Weight

Price Target: $30 → $20

Current: $2.11

Upside: +847.87%

Feb 1, 2023

Initiates: Overweight

Price Target: $45

Current: $2.59

Upside: +1,637.45%

Jan 27, 2023

Maintains: Overweight

Price Target: $20 → $10

Current: $0.68

Upside: +1,371.67%

Jan 27, 2023

Downgrades: Equal-Weight

Price Target: $3

Current: $2.41

Upside: +24.48%

Jan 27, 2023

Upgrades: Equal-Weight

Price Target: $18 → $30

Current: $5.31

Upside: +464.97%

Mar 30, 2022

Maintains: Equal-Weight

Price Target: $25 → $30

Current: $1.22

Upside: +2,359.02%

Oct 8, 2020

Initiates: Outperform

Price Target: $45

Current: $10.02

Upside: +349.10%

May 28, 2020

Maintains: Outperform

Price Target: $12 → $20

Current: $0.33

Upside: +6,053.85%

Nov 3, 2017

Maintains: Outperform

Price Target: $85 → $80

Current: $37.13

Upside: +115.46%

Jul 12, 2017

Maintains: Outperform

Price Target: $12 → $15

Current: $5.69

Upside: +163.62%